Salmon Se
About
In The Last Decade
Salmon Se
34 papers receiving 881 citations
Peers
Comparison fields: 5 of 96
- Molecular Biology 474
- Oncology 422
- Hematology 300
- Cancer Research 142
- Radiology, Nuclear Medicine and Imaging 108
Countries citing papers authored by Salmon Se
This map shows the geographic impact of Salmon Se's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Salmon Se with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Salmon Se more than expected).
Fields of papers citing papers by Salmon Se
This network shows the impact of papers produced by Salmon Se. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Salmon Se. The network helps show where Salmon Se may publish in the future.
Co-authorship network of co-authors of Salmon Se
This figure shows the co-authorship network connecting the top 25 collaborators of Salmon Se. A scholar is included among the top collaborators of Salmon Se based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Salmon Se. Salmon Se is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Relevance of multidrug resistance to rheumatoid arthritis: development of a new therapeutic hypothesis. | 27 |
| 2 | Idiotype specific peptides bind to the surface immunoglobulins of two murine B-cell lymphoma lines, inducing signal transduction. | 12 |
| 3 | Hemopoietic stem cell transplants for multiple myeloma. | 12 |
| 4 | In vitro evaluation of anticancer drugs with the human tumor stem cell assay. | 45 |
| 5 | New drugs in ovarian cancer and malignant melanoma: in vitro phase II screening with the human tumor stem cell assay. | 68 |
| 6 | Clinical correlations of in vitro drug sensitivity. | 58 |
| 7 | Soft agar-methylcellulose assay for human bladder carcinoma. | 3 |
| 8 | Development of a bioassay for ovarian carcinoma colony-forming cells. | 9 |
| 9 | Cloning of Human tumor stem cells: background and overview. | 9 |
| 10 | In vitro drug assay: pharmacologic considerations. | 41 |
| 11 | Salvage treatment of patients relapsing after breast cancer adjuvant chemotherapy. | 15 |
| 12 | Discrimination between human T and B lymphocytes by computer analysis of digitized data from scanning microphotometry. II. Discrimination and automated classification. | 2 |
| 13 | A new basis for treatment of multiple myeloma. | 1 |
| 14 | Bioassay of human tumor stem cells. A new approach to evaluation and treatment of cancer. | 1 |
| 15 | Combination chemotherapy with adriamycin and cyclophosphamide (with or without radiation therapy) for carcinoma of the lung. | 11 |
| 16 | Nitrosoureas in multiple myeloma. | 26 |
| 17 | Combination chemotherapy with adriamycin (NSC-123127) and cyclophosphamide (NSC-26271) for solid tumors: a phase II trial. | 33 |
| 18 | Adriamycin (NSC-123127) in the treatment of alkylator-resistant multiple myeloma: a pilot study. | 35 |
| 19 | Immunoglobulin synthesis and tumor kinetics of multiple myeloma. | 122 |
| 20 | Intermittent high-dose prednisone (NSC-10023) therapy for multiple myeloma. | 38 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.